DISPARATE SUICIDE CARRIER CELLS FOR TUMOR TARGETING OF PROMISCUOUS ONCOLYTIC VIRUSES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jul 18, 2007
filing date -
Jul 18, 2006
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic. The lytic phase of the carrier cell infection is staged so that the carrier is administered in an eclipse phase, and lysis follows the conclusion of the therapeutic targeting interval.
First Claim
Other Claims data not available